Amgen Inc. [NASDAQ: AMGN] gained 5.55% or 15.37 points to close at $292.39 with a heavy trading volume of 6903347 shares. The company report on November 7, 2022 that AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes. Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE. It opened the trading session at $282.565, the shares rose to $296.67 and dropped to $282.22, the range by which the price of stock traded the whole day. The daily chart for AMGN points out that the company has recorded 21.47% gains over the past six months. However, it is still -47.2% lower than its most recent low trading price. If we look at the average trading volume of 2.67M shares, AMGN reached to a volume of 6903347 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Amgen Inc. [AMGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMGN shares is $258.46 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMGN stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Amgen Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 31, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price from $257 to $279. The new note on the price target was released on October 11, 2022, representing the official price target for Amgen Inc. stock. Previously, the target price had yet another raise to $256, while SVB Leerink analysts kept a Mkt Perform rating on AMGN stock. On February 09, 2022, analysts increased their price target for AMGN shares from 210 to 250.
The Average True Range (ATR) for Amgen Inc. is set at 7.12, with the Price to Sales ratio for AMGN stock in the period of the last 12 months amounting to 5.89. The Price to Book ratio for the last quarter was 64.69, with the Price to Cash per share for the same quarter was set at 13.51. Price to Free Cash Flow for AMGN in the course of the last twelve months was 36.59 with Quick ratio for the last quarter at 1.20.
Trading performance analysis for AMGN stock
Amgen Inc. [AMGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.47. With this latest performance, AMGN shares gained by 25.95% in over the last four-week period, additionally plugging by 21.47% over the last 6 months – not to mention a rise of 38.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMGN stock in for the last two-week period is set at 78.35, with the RSI for the last a single of trading hit 82.24, and the three-weeks RSI is set at 74.59 for Amgen Inc. [AMGN]. The present Moving Average for the last 50 days of trading for this stock 245.12, while it was recorded at 274.67 for the last single week of trading, and 241.96 for the last 200 days.
Amgen Inc. [AMGN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Amgen Inc. [AMGN] shares currently have an operating margin of +35.22 and a Gross Margin at +75.16. Amgen Inc.’s Net Margin is presently recorded at +22.68.
Return on Equity for this stock inclined to 73.16, with Return on Assets sitting at 9.50.
Amgen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.50.
Amgen Inc. [AMGN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amgen Inc. go to 7.67%.
An analysis of insider ownership at Amgen Inc. [AMGN]
There are presently around $122,252 million, or 79.90% of AMGN stock, in the hands of institutional investors. The top three institutional holders of AMGN stocks are: BLACKROCK INC. with ownership of 46,825,552, which is approximately -6.402% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 46,148,617 shares of the stock with an approximate value of $13.49 billion in AMGN stocks shares; and STATE STREET CORP, currently with $8.56 billion in AMGN stock with ownership of nearly -4.011% of the company’s market capitalization.
Positions in Amgen Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 1,058 institutional holders increased their position in Amgen Inc. [NASDAQ:AMGN] by around 20,210,172 shares. Additionally, 994 investors decreased positions by around 23,245,276 shares, while 382 investors held positions by with 374,657,490 shares. The mentioned changes placed institutional holdings at 418,112,938 shares, according to the latest SEC report filing. AMGN stock had 118 new institutional investments in for a total of 1,988,789 shares, while 99 institutional investors sold positions of 1,032,664 shares during the same period.